TL;DR
This paper systematically reconciles various disease-drug connectivity scores used in drug repurposing, providing a unified framework for clearer comparison and future method development.
Contribution
It introduces a consistent notation and terminology for multiple connectivity metrics, enabling better comparison and integration of drug repurposing approaches.
Findings
Unified scheme for connectivity scores and similarity metrics
Enhanced clarity and interpretability of drug-disease signature relationships
Facilitates comparison and development of new drug repurposing methods
Abstract
The basis of several recent methods for drug repurposing is the key principle that an efficacious drug will reverse the disease molecular 'signature' with minimal side-effects. This principle was defined and popularized by the influential 'connectivity map' study in 2006 regarding reversal relationships between disease- and drug-induced gene expression profiles, quantified by a disease-drug 'connectivity score.' Over the past 15 years, several studies have proposed variations in calculating connectivity scores towards improving accuracy and robustness in light of massive growth in reference drug profiles. However, these variations have been formulated inconsistently using various notations and terminologies even though they are based on a common set of conceptual and statistical ideas. Therefore, we present a systematic reconciliation of multiple disease-drug similarity metrics (ES,…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Code & Models
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
